Fubini Ross 4

What Happened

• Fubini Ross, a non-employee director of Ginkgo Bioworks Holdings, Inc. (DNA), was granted 25,000 restricted stock units (RSUs) on June 11, 2026. The award is reported as a derivative acquisition (code A) and no per-share price is reported (N/A) because RSUs are compensation, not an open-market trade.
• These RSUs represent a contingent right to receive one share of the issuer’s Class A common stock per unit upon vesting. This is a compensation grant rather than a purchase or sale.

Key Details

• Transaction date: 2026-06-11; Filing date (Form 4): 2026-06-15 (filed within the typical 2-business-day window).
• Instrument: 25,000 Restricted Stock Units (RSUs); price: N/A (compensation award).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes:
  • F1 — Each RSU converts to one share of Class A common stock upon settlement.
  • F2 — RSUs vest on the earlier of June 11, 2027 or the day immediately before the next Annual Meeting after the grant date, contingent on Ross continuing service as a non-employee director.
• Transaction code: A = Award/Grant (derivative).

Context

• RSU grants to directors are routine compensation and do not transfer stock ownership until vesting/settlement, so they do not indicate an immediate buy or sell decision.
• For retail investors, director RSU grants are useful to monitor for future insider holdings but should not be interpreted as an immediate market signal.